Oral semaglutide is its own formulation
Current Wegovy tablets are an approved oral semaglutide product with specific administration directions. They are different from both Wegovy injection and a compounded oral semaglutide offer.[source]
Ask whether the daily routine and instructions fit your circumstances. A tablet should not be described as a weekly injection made easier without acknowledging the formulation-specific requirements.
Single-dose presentations contain one dose
A Zepbound single-dose vial and single-dose pen each hold one dose, but the handling differs. The manufacturer describes the pen as having a built-in needle and the vial as requiring a needle and syringe.[source]
Get instruction for the exact presentation supplied. Do not apply a video, label or volume assumption from another product because the ingredient name matches.
A KwikPen holds multiple doses for one patient
Zepbound KwikPen contains four weekly doses. It uses a new pen needle for each injection and must not be shared between patients, even when the needle is changed.[source][source]
It is distinct from the single-dose Zepbound pen. A review or quote should say which format is intended, including whether supplies are included.
A vial does not automatically mean compounded
Branded Zepbound is available in a vial, and compounded medicines may also be supplied in vials. Packaging alone cannot establish approval status. Confirm the complete product name, manufacturer or compounding pharmacy and label.
FDA’s guidance on unapproved GLP-1 products is relevant when evaluating a compounded preparation, including concerns about dosing errors and semaglutide salt forms.[source]
Match the format before comparing price or evidence
The SURMOUNT-5 trial did not test current oral Wegovy. Manufacturer savings programs can also distinguish between delivery formats. The useful comparison records formulation, dose, supplies, care and the actual payment terms together.[source]
Our product reviews keep these combinations separate rather than assigning one price or trial percentage to an entire ingredient category.
Sources & further reading
Provider pages establish what a brand markets. Clinical and regulatory sources establish the limits of the evidence. Each source has its own last-checked date below.
- Wegovy prescribing informationManufacturer labeling; formulation-specific directions and safety information · Checked October 8, 2026
- LillyDirect: Zepbound formats and pricesManufacturer fulfillment and self-pay program terms · Checked October 8, 2026
- Zepbound prescribing informationManufacturer prescribing information, warnings and approved uses · Checked October 8, 2026
- FDA: concerns with unapproved GLP-1 drugsCompounded-product risks, salt forms, dosing errors and online red flags · Checked October 10, 2026
- Aronne et al., NEJM 2025: tirzepatide compared with semaglutide for obesityPrimary randomized trial abstract; SURMOUNT-5, 751 adults without diabetes, 72 weeks; funded by Eli Lilly · Checked October 8, 2026